Nagarajan, S, Rao, S.V, Chernukhin, I, Sutton, J, Cheeseman, D, Dunn, S, Papachristou, E.K, Gonzalez Prada, J-E, Couturier, D-L, Kumar, S, Kishore, K, Chilamakuri, CSR, Glont, S-E, Goode, E.A, Brodie, C, Guppy, N, Natrajan, R, Bruna, A, Caldas, C, Russell, A.I, Siersbæk, R, Yusa, K and Carroll, J. S. ARID1A dictates HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. Nature Genetics, 2020, 52: 187-197
Piggin, C.L, Roden, D.L, Law, A.M.K, Molloy, M.P, Krisp, C, Swarbrick, A, Naylor, M.J, Kalyuga, M, Kaplan, W, Oakes, S.R, Gallego-Ortega, D, Clark, S.J, Carroll, J.S, Bartonicek, N and Ormandy, C.J. ELF5 Modulates the Estrogen Receptor Cistrome in Breast Cancer, PLoS Genet, 2020, 16 (1), e1008531
Pettigrew, T.R, Porter, R.J, Walsh, S.J, Housden, M.P, Lam N.Y.S, Carroll, J.S, Parker J.S, Spring, D.R and Paterson, I. Total Synthesis and Biological Evaluation of Simplified Aplyronine Analogues as Synthetically Tractable Anticancer Agents, Chem Commun, 2020, 56 (10), 1529-1532
Fachal L et al, Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet. 2020, 52(1):56-73
Shu, S, Wu, H.J, Ge, J.Y, Zeid, R, Harris, I.S, Jovanović, B, Murphy, K, Wang, B, Qiu, X, Endress, J.E, Reyes, J, Lim, K, Font-Tello, A, Syamala, S, Xiao, T, Reddy Chilamakuri, C.S, Papachristou, E.K, D'Santos, C, Anand, J, Hinohara, K, Li, W, McDonald, T.O, Luoma, A, Modiste, R.J, Nguyen, Q.D, Michel, B, Cejas, P, Kadoch, C, Jaffe, J.D, Wucherpfennig, K.W, Qi, J, Liu, X.S, Long, H, Brown, M, Carroll, J.S, Brugge, J.S, Bradner, J, Michor, F and Polyak, K. Mol Cell. 2020:S1097-2765
Walsh, S.J, Iegre, J, Seki, H, Bargh, J.D, Sore, H.F, Parker, J.S, Carroll J.S and Spring, D.R. General dual functionalisation of biomacromolecules via a cysteine bridging strategy. Org Biomol Chem. 2020 May 20. doi: 10.1039/d0ob00907e
Hruschka, N, Kalisz, M, Subijana, M, Graña-Castro, O, Del Cano-Ochoa, F, Brunet, L.P, Chernukhin, I, Sagrera, A, De Reynies, A, Kloesch, B, Chin, S-F, Burgués, O, Andreu, D, Bermejo, B, Cejalvo, J.M, Sutton, J, Caldas, C, Ramón-Maiques, S, Carroll, J.S, Prat, A, Real, F.X and Martinelli P.The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. Oncogene. 2020. 39(32):5455-5467
Baker, L.A, Holliday, H, Roden, D, Krisp, C, Wu, S.Z, Junankar, S, Serandour, A.A, Mohammed, H, Nair, R, Sankaranarayanan, G, Law, A.M.K, McFarland, A, Simpson, P.T, Lakhani, S, Dodson, E, Selinger, C, Anderson, L, Samimi, G, Hacker, N.F, Lim, E, Ormandy, C.J, Naylor, M.J, Simpson, K, Nikolic, I, O'Toole, S, Kaplan, W, Cowley, M.J, Carroll, J.S, Molloy, M and Swarbrick, A. Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. Breast Cancer Res. 2020 Jun 11;22(1):63. doi: 10.1186/s13058-020-01306-6
Siersbæk, R, Scabia, V, Nagarajan, S, Chernukhin, I, Papachristou, E.K, Broome, R, Johnston, S.J, Joosten, S.E.P, Green, A.R, Kumar, S, Jones, J, Omarjee, S, Ruben, A, Glont, S, Aitken, S.J, Kishore, K, Cheeseman, D, Rakha, E.A, D’Santos, C, Zwart, W, Russell, A, Brisken, C and Carroll J.S. IL6/STAT3 signaling hijacks ER enhancers to drive breast cancer metastasis. Cancer Cell, 2020, 38: 412-423
Wang, S, Somisetty ,V.S, Bai, B, Chernukhin, I, Niskanen, H, Kaikkonen, M.U, Bellet, M, Carroll, J.S and Hurtado, A. The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen. Oncogene. 2020. doi: 10.1038/s41388-020-01435-4.
Charoenpattarapreeda, J, Walsh, S.J, Carroll, J.S and Spring, D.R. Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics. Angew Chem Int Ed Engl. 2020 Sep 7. doi: 10.1002/anie.202010090
Omarjee, S and Carroll, J.S. Targeting LSD1 and FOXA1 in prostate cancer. Nat Genet. 2020 Oct;52(10):1002-1003
Ali, F.R, Marcos, D, Chernukhin, I, Woods, L.M, Parkinson, L.M, Wylie, L.A, Papkovskaia, T.D, Davies, J.D, Carroll, J.S and Philpott, A. Dephosphorylation of the proneural transcription factor ASCL1 re-engages a latent post-mitotic differentiation programme in neuroblastoma. Mol Cancer Res. 2020 Oct 12:molcanres.0693.2020. doi: 10.1158/1541-7786
Giannoudis, A, Malki, M.I, Rudraraju, B, Mohhamed, H, Menon, S, Liloglou, T, Ali, S, Carroll, J.S and Palmieri, C. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. Breast Cancer Res. 2020 Nov 16;22(1):126. doi: 10.1186/s13058-020-01359-7